Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study
Journal of Psychopharmacology · 05.08.2026
DOI: 10.1177/02698811261473401 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Psychopharmacology, online erschienen am 05.08.2026. Verfasst von Fatemeh Ahmadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: ICES, ON, Canada. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ICES Western site, ministry of health, ontario, ontario ministry of health and long-term care.
Abstract (Originalsprache)
Rationale
Initiating an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in patients taking lithium may increase the concentration of serum lithium and the risk of lithium toxicity.
Objective
In patients taking lithium, to compare the 90-day risk of lithium toxicity following a new co-prescription of an ACEi or ARB versus a new co-prescription of a beta-blocker.
Methods
Population-based cohort study in Ontario, Canada, from 2002 to 2024. Patients 50 years of age and older taking lithium who were co-prescribed an oral ACEi or ARB ( n = 2267) or a beta-blocker ( n = 2110). Outcomes were assessed within 90 days of initiating the drug co-prescription. The primary outcome was a hospital admission with lithium toxicity. Secondary outcomes were all-cause mortality and all-cause hospitalization. Overlap weighting using propensity scores was used to balance groups on indicators of baseline health. Risk ratios (RR) were obtained using weighted log-binomial regression, and risk differences (RD) were obtained using weighted binomial regression.
Results
In lithium users, co-prescription of an ACEi or ARB versus a beta-blocker was not associated with a higher risk of hospital admission with lithium toxicity (47/2267 patients co-prescribed an ACEi or ARB (2.1%) versus 54/2110 patients co-prescribed a beta-blocker (2.6%); weighted RR 0.72 (95% CI, 0.47 to 1.11); weighted RD −0.75% (95% CI, −1.74% to 0.25%). In lithium users, co-prescription of an ACEi or ARB versus a beta-blocker was not associated with a higher risk of all-cause mortality or all-cause hospitalization.
Conclusion
The findings of this study suggest that the higher risk of lithium toxicity in patients co-prescribed an ACEi or ARB observed in some prior studies may be overstated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ICES, ON, Canada.
- Department of Epidemiology and Biostatistics, Western University, ON, Canada.
- London Health Sciences Centre Research Institute, London Health Sciences Centre, ON, Canada.
- Department of Physiology and Pharmacology, Western University, London, ON, Canada.
- Division of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
ORCID-Profile: Fatemeh Ahmadi, Flory Tsobo Muanda
Förderung
- ICES Western site
- ministry of health, ontario
- ontario ministry of health and long-term care
- academic medical organization of southwestern ontario
- schulich school of medicine and dentistry, western university
- lawson health research institute
Zitieren
APA
Ahmadi, F., Muanda, F. T., McArthur, E., Weir, M., & Garg, A. X. (2026). Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study. Journal of Psychopharmacology. https://doi.org/10.1177/02698811261473401
Vancouver
Ahmadi F, Muanda FT, McArthur E, Weir M, Garg AX. Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study. Journal of Psychopharmacology. 2026. doi:10.1177/02698811261473401
BibTeX
@article{Ahmadi2026,
author = {Ahmadi, Fatemeh and Muanda, Flory Tsobo and McArthur, Eric and Weir, Matthew and Garg, Amit X},
title = {Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study},
journal = {Journal of Psychopharmacology},
year = {2026},
doi = {10.1177/02698811261473401}
}
EUVIMED